$MTEX

Nasdaq Deficiency. On April 20, 2026, Mannatech, Incorporated received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC…

MANNATECH INC (MTEX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. Nasdaq Deficiency. On April 20, 2026, Mannatech, Incorporated (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stock

Original reporting
Published Oct 14, 2026, 9:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$MTEX
Bearish
high confidence
Mentioned
$MTEX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MTEXBearishMed
01

Why it matters

The filing introduces new compliance risk, likely prompting short‑term selling pressure while investors await Nasdaq's final decision.

02

Market read

The news creates immediate trading relevance for MTEX due to potential delisting risk and uncertainty around the company's equity remediation.

03

What to watch

Potential tax benefit from reduced Swiss withholding could improve cash flow, offsetting equity concerns.

Relevance 6/10Novelty 7/10Timing: immediate after filing

Background

Mannatech filed an 8‑K reporting a Nasdaq deficiency due to negative stockholders’ equity and announced a share purchase to acquire full ownership of its Swiss subsidiary, which it says improves equity on a pro‑forma basis.

Company-level read

Ticker impact

$MTEXBearishHigh confidence
Context

Nasdaq notified Mannatech (MTEX) of non‑compliance with the $2.5M stockholders’ equity requirement and the company claims it has regained compliance via a share purchase.

Expected impact

downward pressure as investors weigh the uncertainty of continued Nasdaq listing.

Evidence & confidence

The filing is the first public disclosure of the deficiency and the company's remedial plan; market typically reacts negatively to listing‑rule breaches.

Market effects

Raises scrutiny on other small‑cap Nasdaq issuers with weak equity positions.

Limited to U.S. equity markets; no broader regional effect.

Minimal global impact; primarily a micro‑cap listing issue.

Counterpoint

If the pro‑forma adjustment holds, the stock may rebound once compliance is confirmed.

Key entities

  • Mannatech, Inc.

    Subject of the Nasdaq deficiency notice and the share purchase transaction.

  • Nasdaq Stock Market LLC

    Issuer of the listing‑rule deficiency notice.

Related articles

$MTEXMed

Mannatech Reports Financial Results for Second Quarter 2026

MANNATECH INC (MTEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mannatech Reports Financial Results for Second Quarter 2026 (Flower Mound, Texas) August 12, 2026 - Mannatech, Incorporated (NASDAQ: MTEX ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today a

$INMBMedAI 8/10

INmune Bio submits pre-approval package to UK regulator for RDEB

INmune Bio (INMB) submitted a pre-Marketing Authorisation Application to the UK regulator for its cell therapy Ebstrocel, aiming for a full submission in early 2027. The company expects a UK response within 3-6 months and plans to submit a U.S. application in Q2 2027, prioritizing the FDA over the EMA. Ebstrocel is still in clinical development and has not been approved.

$UNCYMed

FDA accepts Unicycive resubmission for kidney disease drug

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmission for oxylanthanum carbonate, a drug for chronic kidney disease. The FDA set a target action date of March 25, 2027, and the resubmission includes data from a new manufacturing vendor. The company received a Complete Response Letter in June 2026 due to issues with the original manufacturer. Unicycive seeks approval via the 505(b)(2) pathway.

$IRDMedAI 8/10

Opus Genetics receives FDA clearance for RDH12-LCA gene therapy

Opus Genetics (NASDAQ:IRD) received FDA clearance for its gene therapy OPGx-RDH12, targeting RDH12-associated Leber congenital amaurosis. The company plans to start a Phase 1/2 trial this quarter. The therapy aims to restore retinal function in a rare inherited disease affecting 30,900 people globally. Opus Genetics collaborates with the Global RDH12 Alliance, which committed up to $1.6 million for development.